-
公开(公告)号:US5798379A
公开(公告)日:1998-08-25
申请号:US994029
申请日:1997-12-18
申请人: Tamio Mizukami , Harumi Ogawa , Ryuichiro Nakai , Akira Asai , Yoshinori Yamashita , Katsuhiko Ando , Tsutomu Agatsuma , Shiro Akinaga , Kozo Ouchi , Hideki Kawasaki
发明人: Tamio Mizukami , Harumi Ogawa , Ryuichiro Nakai , Akira Asai , Yoshinori Yamashita , Katsuhiko Ando , Tsutomu Agatsuma , Shiro Akinaga , Kozo Ouchi , Hideki Kawasaki
IPC分类号: C07D487/04 , C07D491/16 , C12P17/14 , A61K31/40 , C07D487/02
CPC分类号: C07D487/04 , C12P17/14
摘要: UCS1025 compounds represented by the following formula (I): ##STR1## wherein R represents hydrogen or hydroxyl group, or tautomers or pharmacologically acceptable salts thereof.
摘要翻译: 由下式(I)表示的UCS1025化合物:其中R表示氢或羟基,或互变异构体或其药理学上可接受的盐。
-
公开(公告)号:US5965604A
公开(公告)日:1999-10-12
申请号:US215468
申请日:1998-12-17
申请人: Yoshinori Yamashita , Ryuichiro Nakai , Tamio Mizukami , Shingo Kakita , Shigeru Chiba , Shiro Akinaga
发明人: Yoshinori Yamashita , Ryuichiro Nakai , Tamio Mizukami , Shingo Kakita , Shigeru Chiba , Shiro Akinaga
IPC分类号: A61K31/365 , A61P31/04 , A61P35/00 , C07D493/18 , C07D493/20 , C12P17/18 , C12R1/465 , A01N43/08 , A01N43/02 , C07D307/77 , C12P17/08
CPC分类号: C07D493/20 , C12P17/181 , C12R1/465 , Y10S435/886
摘要: The present invention relates to chrolactomycin compound represented by the following formula (I): ##STR1## or pharmaceutically acceptable salts thereof having antibacterial and antitumor activities.
摘要翻译: 本发明涉及由下式(I)表示的己内酰霉素化合物或其药学上可接受的盐,其具有抗细菌和抗肿瘤活性。
-
公开(公告)号:US20100029625A1
公开(公告)日:2010-02-04
申请号:US11993757
申请日:2006-06-22
IPC分类号: A61K31/433 , C07D285/135 , C07D417/12 , C07D491/056 , A61K31/506 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K31/438 , A61P9/00
CPC分类号: A61K31/433 , C07D285/12 , C07D285/135 , C07D417/12 , C07D491/10
摘要: A therapeutic and/or prophylactic agent for restenosis, which comprises a thiadiazoline derivative represented by the general formula (0), or a pharmaceutically acceptable salt thereof: [wherein, n represents an integer of 1 to 3, R0 represents aryl, —NR1CONR2 (wherein R1 represents a hydrogen atom or the like, and R2 represents lower alkyl or the like) or the like, R3 represents lower alkyl, R4 represents a hydrogen atom or the like, and R5 represents aryl or the like].
摘要翻译: 用于再狭窄的治疗和/或预防剂,其包含由通式(0)表示的噻二唑啉衍生物或其药学上可接受的盐:[其中,n表示1至3的整数,R 0表示芳基,-NR 1 CONR 2( 式中,R 1表示氢原子等,R 2表示低级烷基等),R 3表示低级烷基,R 4表示氢原子等,R 5表示芳基等。
-
公开(公告)号:US20080207706A1
公开(公告)日:2008-08-28
申请号:US12098736
申请日:2008-04-07
申请人: Chikara MURAKATA , Kazuhiko Kato , Yoshihisa Ohta , Ryuichiro Nakai , Yoshinori Yamashita , Takeshi Takahashi , Tomohisa Nakano , Yoji Ino
发明人: Chikara MURAKATA , Kazuhiko Kato , Yoshihisa Ohta , Ryuichiro Nakai , Yoshinori Yamashita , Takeshi Takahashi , Tomohisa Nakano , Yoji Ino
IPC分类号: A61K31/433 , A61P35/00
CPC分类号: C07D285/135 , A61K31/433 , A61K31/4439 , A61K31/497 , A61K31/5377
摘要: (wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R5 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —C(═W)R6 or the like; R3 represents a hydrogen atom, —C(═WA)R6A, or the like)Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.
摘要翻译: (其中R 1和R 4相同或不同,各自表示氢原子,取代或未取代的低级烷基,取代或未取代的低级炔基,取代或未取代的低级链烯基 等等; R 5表示取代或未取代的杂环基,取代或未取代的芳基等; R 2表示-C(-W)R SUP > 6个等等; R 3表示氢原子,-C(-W A)SO 6,或者 提供包含由上述通式(I)表示的噻二唑啉衍生物或其药理学上可接受的盐作为有效成分的抗肿瘤剂。
-
公开(公告)号:US20070155804A1
公开(公告)日:2007-07-05
申请号:US10553222
申请日:2004-04-16
申请人: Chikara Murakata , Yoshinori Yamashita , Ryuichiro Nakai , Kazuhito Akasaka , Yoji Ino , Kazuhiko Kato , Yushi Kitamura
发明人: Chikara Murakata , Yoshinori Yamashita , Ryuichiro Nakai , Kazuhito Akasaka , Yoji Ino , Kazuhiko Kato , Yushi Kitamura
IPC分类号: A61K31/433 , C07D285/12 , C07D417/02
CPC分类号: C07D285/13 , A61K31/433 , A61K31/4439 , A61K31/506 , A61K31/5377 , C07D285/135
摘要: A mitotic kinesin Eg5 inhibitor which comprises a thiadiazoline derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient: [wherein R1 represents a hydrogen atom and the like, R2 represents a hydrogen atom, —C(═W)R6 (wherein W represents an oxygen atom or a sulfur atom, and R6 represents substituted or unsubstituted lower alkyl and the like) and the like, R3 represents —C(═Z)R19 (wherein Z represents an oxygen atom or a sulfur atom, and R19 represents substituted or unsubstituted lower alkyl and the like) and the like, R4 represents substituted or unsubstituted lower alkyl and the like, and R5 represents substituted or unsubstituted aryl and the like] and the like are provided.
摘要翻译: 一种有丝分裂驱动蛋白Eg5抑制剂,其包含由通式(I)表示的噻二唑啉衍生物或其药理学上可接受的盐作为有效成分:[其中R 1表示氢原子等, O 2表示氢原子,-C(-W)R 6(其中W表示氧原子或硫原子,R 6表示 取代或未取代的低级烷基等)等,R 3表示-C(-Z)R 19(其中Z表示氧原子或硫原子, 和R 19表示取代或未取代的低级烷基等)等,R 4表示取代或未取代的低级烷基等,R 5, / SUP>表示取代或未取代的芳基等〕等。
-
公开(公告)号:US07745641B2
公开(公告)日:2010-06-29
申请号:US11918778
申请日:2006-04-19
申请人: Chikara Murakata , Nobuyoshi Amishiro , Toshiyuki Atsumi , Yoshinori Yamashita , Takeshi Takahashi , Ryuichiro Nakai , Hisashi Tagaya , Hiroko Takahashi , Jun Funahashi , Junichiro Yamamoto , Yuichi Fukuda
发明人: Chikara Murakata , Nobuyoshi Amishiro , Toshiyuki Atsumi , Yoshinori Yamashita , Takeshi Takahashi , Ryuichiro Nakai , Hisashi Tagaya , Hiroko Takahashi , Jun Funahashi , Junichiro Yamamoto , Yuichi Fukuda
IPC分类号: C07D207/00 , A61K31/40
CPC分类号: C07D209/46 , C07D209/48 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D471/04
摘要: The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): {wherein W represents a nitrogen atom or —CH—; X represents —C(═O)— or —CHR4— (wherein R4 represents a hydrogen atom, or the like}; R1 represents a group represented by the following formula: [wherein Q1 represents a nitrogen atom or —CR8— (wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like). Q2 represents —NR15— (wherein R15 represents a hydrogen atom, or the like) and R5 and R6 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like]; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof, and the like.
摘要翻译: 本发明提供由式(I)表示的含氮杂环化合物:其中W表示氮原子或-CH-; X表示-C(= O) - 或-CHR 4 - (其中R 4表示氢原子等); R 1表示由下式表示的基团:[其中Q1表示氮原子或-CR 8 - (其中R 8 表示氢原子,取代或未取代的低级烷基等),Q2表示-NR15-(式中,R15表示氢原子等),R5和R6可以相同或不同,表示氢原子, 取代或未取代的低级烷基等); R 2和R 3可以相同或不同,各自表示氢原子,卤素,取代或未取代的低级烷基等,或其药学上可接受的盐等 。
-
公开(公告)号:US20090054407A1
公开(公告)日:2009-02-26
申请号:US11918778
申请日:2006-04-19
申请人: Chikara Murakata , Nobuyoshi Amishiro , Toshiyuki Atsumi , Yoshinori Yamashita , Takeshi Takahashi , Ryuichiro Nakai , Hisashi Tagaya , Hiroko Takahashi , Jun Funahashi , Junichiro Yamamoto , Yuichi Fukuda
发明人: Chikara Murakata , Nobuyoshi Amishiro , Toshiyuki Atsumi , Yoshinori Yamashita , Takeshi Takahashi , Ryuichiro Nakai , Hisashi Tagaya , Hiroko Takahashi , Jun Funahashi , Junichiro Yamamoto , Yuichi Fukuda
IPC分类号: A61K31/55 , C07D209/04 , A61K31/404 , C07D403/14 , A61K31/496 , C07D401/14 , A61K31/541 , A61K31/506 , A61P35/00 , C07D417/14 , A61K31/454 , C07D413/14 , A61K31/5377 , A61K31/4439
CPC分类号: C07D209/46 , C07D209/48 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D471/04
摘要: The present invention provides a nitrogen-containing heterocyclic compound represented by formula (I): {wherein W represents a nitrogen atom or —CH—; X represents —C(═O)— or —CHR4— (wherein R4 represents a hydrogen atom, or the like); R1 represents a group represented by the following formula: [wherein Q1 represents a nitrogen atom or —CR8— (wherein R8 represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like). Q2 represents —NR15— (wherein R15 represents a hydrogen atom, or the like) and R5 and R6 may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, or the like]; and R2 and R3 may be the same or different and each represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like} or a pharmaceutically acceptable salt thereof, and the like.
摘要翻译: 本发明提供由式(I)表示的含氮杂环化合物:其中W表示氮原子或-CH-; X表示-C(-O) - 或-CHR 4 - (其中R 4表示氢原子等); R1表示由下式表示的基团:[其中Q1表示氮原子或-CR8-(其中R8表示氢原子,取代或未取代的低级烷基等)。 Q2表示-NR15-(其中R15表示氢原子等),R5和R6可以相同或不同,表示氢原子,取代或未取代的低级烷基等]。 R 2和R 3可以相同或不同,各自表示氢原子,卤素,取代或未取代的低级烷基等}或其药学上可接受的盐等。
-
公开(公告)号:US20080262049A1
公开(公告)日:2008-10-23
申请号:US11909324
申请日:2006-03-22
IPC分类号: A61K31/433 , C07D285/08 , A61P35/00 , A61P35/04
CPC分类号: A61K31/433 , A61K31/454 , C07D285/135 , C07D417/04
摘要: A therapeutic and/or prophylactic agent for a hematopoietic tumor, which comprises a thiadiazoline derivative represented by the general formula (I), or a pharmaceutically acceptable salt thereof:[Formula 1] [wherein, n represents an integer of 1 to 3, R1 represents a hydrogen atom, R2 represents lower alkyl, or R1 and R2 are combined together to represent alkylene, R3 represents lower alkyl, R4 represents NHSO2R6 (wherein R6 represents hydroxy or the like) or the like, and R5 represents aryl or the like] and the like are provided.
摘要翻译: 包含通式(I)表示的噻二唑啉衍生物或其药学上可接受的盐的造血肿瘤的治疗和/或预防剂:[式1] [其中,n表示1〜3的整数,R 代表氢原子,R 2表示低级烷基,或R 1和R 2结合在一起至 表示亚烷基,R 3表示低级烷基,R 4表示NHSO 2 R 6(其中R 0) 6表示羟基等)等,R 5表示芳基等]等。
-
公开(公告)号:US07910611B2
公开(公告)日:2011-03-22
申请号:US11993757
申请日:2006-06-22
IPC分类号: A61K31/41
CPC分类号: A61K31/433 , C07D285/12 , C07D285/135 , C07D417/12 , C07D491/10
摘要: A therapeutic and/or prophylactic agent for restenosis, which comprises a thiadiazoline derivative represented by the general formula (0), or a pharmaceutically acceptable salt thereof: [wherein, n represents an integer of 1 to 3, R0 represents aryl, —NR1CONR2 (wherein R1 represents a hydrogen atom or the like, and R2 represents lower alkyl or the like) or the like, R3 represents lower alkyl, R4 represents a hydrogen atom or the like, and R5 represents aryl or the like].
摘要翻译: 用于再狭窄的治疗和/或预防剂,其包含由通式(0)表示的噻二唑啉衍生物或其药学上可接受的盐:[其中,n表示1至3的整数,R 0表示芳基,-NR 1 CONR 2( 式中,R 1表示氢原子等,R 2表示低级烷基等),R 3表示低级烷基,R 4表示氢原子等,R 5表示芳基等。
-
公开(公告)号:US07902234B2
公开(公告)日:2011-03-08
申请号:US12792448
申请日:2010-06-02
申请人: Chikara Murakata , Kazuhiko Kato , Yoshihisa Ohta , Ryuichiro Nakai , Yoshinori Yamashita , Takeshi Takahashi
发明人: Chikara Murakata , Kazuhiko Kato , Yoshihisa Ohta , Ryuichiro Nakai , Yoshinori Yamashita , Takeshi Takahashi
IPC分类号: A61K31/433 , C07D285/125
CPC分类号: C07D285/135 , A61K31/433 , A61K31/4439 , A61K31/497 , A61K31/5377
摘要: (wherein R1 and R4 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted lower alkenyl, or the like; R6 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —C(═W)R6 or the like; R3 represents a hydrogen atom, —C(═WA)R6A, or the like)Antitumor agents which comprises a thiadiazoline derivative represented by the aforementioned general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient are provided.
摘要翻译: (其中R 1和R 4相同或不同,各自表示氢原子,取代或未取代的低级烷基,取代或未取代的低级炔基,取代或未取代的低级烯基等; R 6表示取代或未取代的杂环基,取代或未取代的 未取代的芳基等; R 2表示-C(= W)R 6等; R 3表示氢原子,-C(= W)R 6 A等)。 提供包含由上述通式(I)表示的噻二唑啉衍生物或其药理学上可接受的盐作为活性成分的抗肿瘤剂。
-
-
-
-
-
-
-
-
-